Vascular Biogenics Ltd (VBLT)

[sys483]

I find it interesting that in the results you posted (reported by HC) it says:

“In the previous Phase 2 study, patients treated with VB-111 plus Avastin achieved a median OS of 15 months, compared to historical OS of 9-12 months for Avastin alone.”

But if you go back to the VBL press release on June 3, 2016 it says:

“In the Phase 2 VB-111 trial, the median overall survival of patients who received continuous exposure of VB-111 in combination with Avastin was 59 weeks. This is compared to 32 weeks in the pooled data from the 8 studies in the meta-analysis (p= 0.0295; Hazard Ratio 0.62, 95% CI: 0.40-0.96).”

The Avastin comparison of 9-12 months reported by HC vs. 32 weeks (8 months) reported by VBL is significantly different, at least in my mind. Am I missing something?